Literature DB >> 29386864

Betrixaban (Bevyxxa): A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor.

Jessica W Skelley, Angela R Thomason, Jeffery C Nolen, PharmD Candidate.   

Abstract

Betrixaban (Bevyxxa): a direct-acting oral anti-coagulant factor Xa inhibitor.

Entities:  

Year:  2018        PMID： 29386864      PMCID： PMC5768296     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  21 in total

1.  Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

Authors:  Samuel Z Goldhaber; Alain Leizorovicz; Ajay K Kakkar; Sylvia K Haas; Geno Merli; Robert M Knabb; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

Review 2.  Reversal of anticoagulants: an overview of current developments.

Authors:  Andreas Greinacher; Thomas Thiele; Kathleen Selleng
Journal:  Thromb Haemost       Date:  2015-04-02       Impact factor: 5.249

Review 3.  Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Samantha MacLean; Sohail Mulla; Elie A Akl; Milosz Jankowski; Per Olav Vandvik; Shanil Ebrahim; Shelley McLeod; Neera Bhatnagar; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score.

Authors:  S Barbar; F Noventa; V Rossetto; A Ferrari; B Brandolin; M Perlati; E De Bon; D Tormene; A Pagnan; P Prandoni
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

5.  Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study.

Authors:  John A Heit; W Michael O'Fallon; Tanya M Petterson; Christine M Lohse; Marc D Silverstein; David N Mohr; L Joseph Melton
Journal:  Arch Intern Med       Date:  2002-06-10

6.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Truman J Milling; John W Eikelboom; C Michael Gibson; John T Curnutte; Alex Gold; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Shelly Goodman; Janet Leeds; Brian L Wiens; Deborah M Siegal; Elena Zotova; Brandi Meeks; Juliet Nakamya; W Ting Lim; Mark Crowther
Journal:  N Engl J Med       Date:  2016-08-30       Impact factor: 91.245

Review 7.  Evaluation of the oral direct factor Xa inhibitor - betrixaban.

Authors:  Michael Palladino; Geno Merli; Lynda Thomson
Journal:  Expert Opin Investig Drugs       Date:  2013-08-22       Impact factor: 6.206

8.  Betrixaban (PRT054021): pharmacology, dose selection and clinical studies.

Authors:  Noel C Chan; Jack Hirsh; Jeffrey S Ginsberg; John W Eikelboom
Journal:  Future Cardiol       Date:  2014-01

Review 9.  Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes?

Authors:  A Sharma; S Chatterjee; E Lichstein; D Mukherjee
Journal:  J Thromb Haemost       Date:  2012-10       Impact factor: 5.824

10.  Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.

Authors:  Alexander T Cohen; Robert A Harrington; Samuel Z Goldhaber; Russell D Hull; Brian L Wiens; Alex Gold; Adrian F Hernandez; C Michael Gibson
Journal:  N Engl J Med       Date:  2016-05-27       Impact factor: 91.245
View more
  4 in total

Review 1.  Safety analysis of apixaban versus warfarin in patients with advanced kidney disease.

Authors:  Michael Bowie; Violet Valencia; Ingrid Perez-Alvarez; Minh-Ha Tran
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

2.  A comparative analysis of the safety profile of direct oral anticoagulants using the FDA adverse event reporting system.

Authors:  Emma P DeLoughery; Joseph J Shatzel
Journal:  Eur J Haematol       Date:  2019-05-06       Impact factor: 2.997

Review 3.  Factors Affecting the Formation and Treatment of Thrombosis by Natural and Synthetic Compounds.

Authors:  Anna Lichota; Eligia M Szewczyk; Krzysztof Gwozdzinski
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923

Review 4.  Updates in Anticoagulation Therapy Monitoring.

Authors:  Hannah L McRae; Leah Militello; Majed A Refaai
Journal:  Biomedicines       Date:  2021-03-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.